Monitor ESMO 2026 (Oct 23-27) for detailed data disclosures from SAFFRON and SANOVO oral presentations, which could drive regulatory filing timelines and peak sales estimates for savolitinib. The Presidential Symposium slot signals high clinical interest and potential for accelerated regulatory pathways.
Price Chart
Executive Summary
HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral presentations at ESMO 2026, including a Presidential Symposium slot for the global SAFFRON study. The SAFFRON and SANOVO studies both previously reported statistically significant improvements in progression-free survival and overall survival. This is a positive clinical milestone that reinforces the savolitinib franchise's regulatory and commercial potential, though no new data or financial figures were released in this filing.
Key Facts
- Two positive Phase III studies of savolitinib + osimertinib selected for oral presentations at ESMO Congress 2026 (Oct 23-27, Madrid).
- Global SAFFRON study (EGFR-mutated NSCLC post-osimertinib with MET overexpression/amplification) selected for Presidential Symposium oral presentation.
- China SANOVO study (previously untreated EGFR-mutated NSCLC with MET overexpression) selected for Proffered Paper oral presentation.
- SAFFRON reported statistically significant improvement in PFS and OS vs platinum-based chemotherapy (Aug 17, 2026).
- SANOVO reported statistically significant improvement in PFS and clinically meaningful OS benefit vs osimertinib monotherapy (Aug 31, 2026).
- Over 30 additional abstracts across fruquintinib, surufatinib, and savolitinib programs to be presented at ESMO.
Financial Impact
No financial figures disclosed. Positive clinical data from two Phase III savolitinib studies supports potential regulatory filings and label expansion, which could meaningfully expand the addressable market for savolitinib in NSCLC.
Risk Factors
- Detailed efficacy and safety data not yet disclosed; abstract results may differ from final presentation.
- Regulatory approval timelines and commercial uptake remain uncertain.
- Competitive landscape in EGFR-mutated NSCLC includes multiple targeted therapy combinations.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000059 |
| Document: hcm-20260924x6k.htm | 0001648257-26-000059 |
| Document: 0001648257-26-000059-index-headers.html | 0001648257-26-000059 |
| Document: 0001648257-26-000059-index.html | 0001648257-26-000059 |
| Document: 0001648257-26-000059.txt | 0001648257-26-000059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $14.34 | awaiting T+60 | awaiting T+60 | $13.80 (−3.77%) |
Oct 26, 2026 1d ago | 6-K | $14.27 | awaiting T+60 | awaiting T+60 | $13.80 (−3.29%) |
Oct 26, 2026 1d ago | Press Release | $14.27 | awaiting T+60 | awaiting T+60 | $13.80 (−3.29%) |
Oct 26, 2026 2d ago | Press Release | $14.34 | awaiting T+60 | awaiting T+60 | $13.80 (−3.77%) |
Oct 21, 2026 6d ago | 6-K | $14.37 | awaiting T+60 | awaiting T+60 | $13.80 (−3.97%) |
Sep 29, 2026 28d ago | 6-K | $14.15 | awaiting T+60 | awaiting T+60 | $13.80 (−2.47%) |
Sep 28, 2026 29d ago | 6-K | $14.15 | awaiting T+60 | awaiting T+60 | $13.80 (−2.47%) |
Sep 29, 2026 29d ago | Press Release | $14.63 | awaiting T+60 | awaiting T+60 | $13.80 (−5.67%) |
Sep 24, 2026 4w ago | 6-K | $13.90 | awaiting T+60 | awaiting T+60 | $13.80 (−0.72%) |
Sep 24, 2026 4w ago | Press Release | $13.94 | awaiting T+60 | awaiting T+60 | $13.80 (−1.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers